HT Bureau
GUWAHATI, Feb 23: Morepen Laboratories Limited has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately ₹825 crore (about USD 91 million) from a leading global pharmaceutical company, marking one of the largest single CDMO orders in the company’s history.
According to the company, supplies under the agreement are expected to begin within the next four to five months, with execution scheduled to continue through the first quarter of the following financial year, subject to operational and regulatory clearances.
Related Posts:
The mandate represents a significant step in Morepen’s strategic expansion into the fast-growing global CDMO segment and strengthens its position as a key manufacturing partner for regulated markets.
With more than four decades of expertise in active pharmaceutical ingredient (API) manufacturing, the company has built a strong regulatory track record supported by internationally accredited facilities, including approvals from the US Food and Drug Administration (USFDA), WHO-GMP and European authorities.
The company said its integrated capabilities — spanning product development to commercial manufacturing — allow it to support complex scale-ups and long-term supply programmes for global pharmaceutical innovators.
It is also evaluating further capacity expansion and technology investments in line with its growing CDMO opportunity pipeline.
Chairman and Managing Director Sushil Suri described the agreement as a major milestone in the company’s manufacturing journey, stating that it reflects the confidence of global customers in Morepen’s quality systems, regulatory compliance and execution capabilities.
He said the CDMO business represents a natural extension of the company’s core API strengths and will provide long-term growth stability.
Kushal Suri, President – International Growth (API), said the mandate validates Morepen’s ability to manage end-to-end technical, regulatory and commercial scale-ups under stringent global standards.
He added that the company now aims to leverage this achievement to secure additional long-term international manufacturing partnerships.
Industry trends indicate that global pharmaceutical firms are increasingly consolidating supplier networks and partnering with reliable, compliant and scalable manufacturers capable of ensuring uninterrupted long-term supply.
Morepen said its vertically integrated API platform and operational scale position it strongly to benefit from this shift in global outsourcing demand.
